26.05
price up icon4.28%   1.07
after-market After Hours: 25.18 -0.87 -3.34%
loading
Harrow Inc stock is traded at $26.05, with a volume of 672.20K. It is up +4.28% in the last 24 hours and down -7.23% over the past month. Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$24.98
Open:
$25.28
24h Volume:
672.20K
Relative Volume:
1.51
Market Cap:
$890.64M
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-27.14
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
-5.79%
1M Performance:
-7.23%
6M Performance:
-43.22%
1Y Performance:
+110.42%
1-Day Range:
Value
$24.63
$26.50
1-Week Range:
Value
$24.32
$30.73
52-Week Range:
Value
$9.86
$59.23

Harrow Inc Stock (HROW) Company Profile

Name
Name
Harrow Inc
Name
Phone
615.733.4731
Name
Address
102 WOODMONT BLVD, NASHVILLE, CA
Name
Employee
217
Name
Twitter
Name
Next Earnings Date
2025-03-17
Name
Latest SEC Filings
Name
HROW's Discussions on Twitter

Compare HROW with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
HROW
Harrow Inc
26.05 890.64M 154.15M -33.58M -20.74M -0.96
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
163.50 72.50B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.98 47.08B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.16 45.99B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.29 17.52B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
312.26 13.78B 2.76B 1.11B 898.10M 22.77

Harrow Inc Stock (HROW) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-06-25 Initiated H.C. Wainwright Buy
Dec-04-24 Reiterated B. Riley Securities Buy
Apr-11-24 Initiated Craig Hallum Buy
Sep-08-22 Resumed B. Riley Securities Buy
Oct-14-21 Resumed B. Riley Securities Buy
Sep-24-21 Initiated Aegis Capital Buy
Jul-02-21 Initiated Ladenburg Thalmann Buy
View All

Harrow Inc Stock (HROW) Latest News

pulisher
Apr 01, 2025

Where Harrow Stands With Analysts - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

B. Riley Adjusts Price Target on Harrow to $65 From $69, Maintains Buy Rating - MarketScreener

Apr 01, 2025
pulisher
Mar 29, 2025

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha

Mar 29, 2025
pulisher
Mar 29, 2025

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance

Mar 29, 2025
pulisher
Mar 28, 2025

Harrow Health Reports Strong 2024 Financial Performance - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 27, 2025

Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Harrow: Q4 Earnings Snapshot - The Advocate

Mar 27, 2025
pulisher
Mar 27, 2025

Harrow Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Joplin Globe

Mar 27, 2025
pulisher
Mar 27, 2025

Harrow Sets Stage for Major 2024 Financial Review: Q4 and Annual Results Coming March 27 - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Harrow Inc. sees $150k stock sale by Opaleye Management - Investing.com

Mar 26, 2025
pulisher
Mar 24, 2025

Harrow sees shares increase following drug approval - Nashville Post

Mar 24, 2025
pulisher
Mar 24, 2025

Craig-Hallum Reaffirms Their Buy Rating on Harrow Health (HROW) - The Globe and Mail

Mar 24, 2025
pulisher
Mar 24, 2025

CMS approves separate reimbursement for Harrow’s TRIESENCE - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire

Mar 24, 2025
pulisher
Mar 24, 2025

TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan

Mar 24, 2025
pulisher
Mar 22, 2025

Harrow Inc (HROW) Shares Up 1.14% on Mar 22 - GuruFocus

Mar 22, 2025
pulisher
Mar 22, 2025

Opaleye management sells $148,200 in Harrow, Inc. stock - Investing.com India

Mar 22, 2025
pulisher
Mar 21, 2025

What To Expect From Harrow Inc (HROW) Q4 2024 Earnings - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Opaleye Management Inc. Adjusts Stake in Harrow Inc. - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Bank of New York Mellon Corp Has $2.90 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Harrow Inc (HROW) Shares Up 2.97% on Mar 21 - GuruFocus

Mar 21, 2025
pulisher
Mar 20, 2025

Opaleye management sells $148,200 in Harrow, Inc. stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 19, 2025

Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial - GlobeNewswire Inc.

Mar 19, 2025
pulisher
Mar 18, 2025

Harrow stock surges on preliminary Q4 numbers - Nashville Post

Mar 18, 2025
pulisher
Mar 18, 2025

Sector Update: Health Care -March 18, 2025 at 08:49 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews

Mar 18, 2025
pulisher
Mar 18, 2025

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga India

Mar 18, 2025
pulisher
Mar 18, 2025

Harrow Reports Preliminary 2024 Q4 and Full-Year Financial Results, Provides 2025 Guidance and Launches New Initiative - VisionMonday.com

Mar 18, 2025
pulisher
Mar 17, 2025

Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi - GuruFocus.com

Mar 17, 2025
pulisher
Mar 17, 2025

Harrow Completes Transfer of the TRIESENCE® New Drug Application - Business Wire

Mar 17, 2025
pulisher
Mar 17, 2025

Harrow Reports Q4 Preliminary Revenue -- Shares Rise After Hours -March 17, 2025 at 04:30 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance - Business Wire

Mar 17, 2025
pulisher
Mar 17, 2025

Harrow Launches VEVYE® Access for All - Business Wire

Mar 17, 2025
pulisher
Mar 17, 2025

Harrow Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga

Mar 17, 2025
pulisher
Mar 15, 2025

HARROW HEALTH Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 15, 2025
pulisher
Mar 11, 2025

Harrow shares react modestly to FDA move | Area Stocks - Nashville Post

Mar 11, 2025
pulisher
Mar 11, 2025

Harrow shares react modestly to FDA move - Nashville Post

Mar 11, 2025
pulisher
Mar 11, 2025

Harrow shares react to FDA move - Nashville Post

Mar 11, 2025
pulisher
Mar 11, 2025

Harrow Signs 5-Year Supply Deal for Triesence -March 11, 2025 at 08:36 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Harrow Executes Five-Year Strategic Supply And Development Agreement For TRIESENCE - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE® - Business Wire

Mar 11, 2025

Harrow Inc Stock (HROW) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$10.77
price up icon 4.06%
$32.65
price up icon 0.37%
$97.42
price down icon 0.52%
$8.66
price up icon 0.70%
$108.31
price up icon 1.22%
$312.26
price up icon 1.75%
Cap:     |  Volume (24h):